National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Implementing NICE guidance
Advanced breast cancer
Metastatic spinal cord compression
Senior Manager – Research Finance & Programmes
1 Attributing the costs of health & social care Research & Development – Understanding AcoRD Trudi Simmons Senior Manager – Research Finance & Programmes.
Local Improvement following National Clinical Audit The View from a National Clinical Audit Provider – the Health & Social Care Information Centre.
Pathway Planning – a model for study initiation or troubleshooting.
NPCA data submission and reporting
EUROCHIP Pilot Study Dr. Finian Bannon Dr. Anna Gavin N. Ireland Cancer Registry Waiting Times & Compliance with Guidelines UK.
NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
National Prostate Cancer Audit Heather Payne, NPCA Oncological Clinical Lead Consultant Clinical Oncologist, UCL.
British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.
National Prostate Cancer Audit: Review of the Organisational Audit Dr Ajay Aggarwal Oncology Coordinator NPCA Honorary.
Northern Trust Lymphoedema Stakeholder Event Elaine Stowe Lymphoedema Lead Northern Trust Feb 2010.
March 2002 Outcomes in thyroid cancer: what factors are important? Information Projects Team Outcomes in thyroid cancer: what factors are important? NYCRIS.
Taxanes for Ovarian Cancer: Progress Report Rosemary Tate Information Projects Team December 2000.
Somerset Cancer Register National Prostate Cancer Audit Conference 5 th December 2014 Ruth McCarthy & Tony Clarke © 2014 Taunton & Somerset NHS Foundation.
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
John Cape Elizabeth Hancock Colleen Roach Miranda Heneghan Lucy Palmer Lorna Farquharson.
ISB Notice and preparing for the implementation of the new IAPT Data Standard Shaun Crowe Mental Health, Employment and IAPT Mental Health Collaborative.
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Background The 2 week wait referral system was designed to expedite the referral of patients, suspected to have cancer, from Primary to Secondary care.
The National Mastectomy and Breast Reconstruction Audit Key findings of the Third Annual Report Slides produced by the MBR Project Team. © The National.
Survivorship Update January 2015 The Royal Wolverhampton NHS Trust James Owen Senior Cancer Services Manager.
ILCOP web conference summary: Histological confirmation rates and diagnostics in lung cancer services 5 th July 2011.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Dr Poonam Valand, Foundation Year Two Dr Anjan Dhar, Consultant Gastroenterologist COUNTY DURHAM AND DARLINGTON NHS FOUNDATION TRUST Early gastric cancer.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
JCUH NICE MSCC Guidelines Compliance audit Ruth Mhlanga Senior Specialist Physiotherapist Oncology and Haematology.
National Oesophago-Gastric Cancer Audit Clinical Audit Platform How to Register, Submit and View Reports CAP: |
A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.
An Integrated Approach to Breast Cancer Control A flexible approach that can be adapted to national or local circumstances.
(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.
Cancer Outcomes and Services Dataset Linda Wintersgill Information & Audit Manager, NECN.
Supporting people with active and advanced disease Need better data collection Discussion at MDT – new diagnosis support Identify best practice Early palliative.
Education resource to support introduction of All Wales Care Decisions for the Last Days of Life All Wales palliative care education group © All Wales.
LUCADA Jacqueline Brown Cancer Services Manager North Tees & Hartlepool Trust.
Cancer Information Framework Initial feedback on NWCN LUCADA submission 2006 data Wednesday 20 th February, 2008 Linda Roberts, Cancer Information Specialist,
Network Audit Patients with Confirmed Small Cell Lung Cancer Who Did Not Receive Chemotherapy Dr D N Leitch On Behalf of Lung Cancer NSSG NECN.
National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.
What data are available, and how are they accessed?
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.
What data are collected? How, and who by? Karen Graham and Barry Plewa.
NCIN Roadshow: Cancer Data NCIN - Cancer Data Roadshow Public Health England | 2015 Elsita Payne Head of Registration – East Midlands and North West Branches.
South West Public Health Observatory South West Regional Public Health Group Opportunities for future analysis by SWPHO Sean McPhail South West Public.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
Training for organisations participating in Peer Review of Paediatric Diabetes.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Gynaecological Oncology Patient Pathway Cecile Bergzoll Gynaecological Oncologist Wellington.
Service user experience in adult mental health NICE quality standard January 2012.
South West Public Health Observatory South West Regional Public Health Group Trends in End of Life Care in the South West Mark Dancox, Andy Pring, Roy.
What data are collected? How, and who by?. It’s complicated… ONS data.
REGIONAL GASTROSTOMY AUDIT FOR HEAD AND NECK CANCER D Bailey 1 D Baldwin 2, S Caldera 3 Cancer Intelligence Service, South.
Title of the Change Project
Oesophago–Gastric Cancer Audit
Oesophago–Gastric Cancer
Delivery of systemic therapy in Gloucestershire for NSCLC
National Oesophago–Gastric Cancer Audit 2015.
Your Symptoms Matter – Prostate Cancer
Curative treatment rates for patients diagnosed with
Oesophago–Gastric Cancer
Treatment breakdown for prostate cancers
National Lung Cancer Audit
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Hannah Marder Cancer Manager UH Bristol
Breast Cancer SSG 14th November
National Lung Cancer Audit
Presentation transcript:

National Prostate Cancer Audit Julie Nossiter, Project Manager Clinical Effectiveness Unit – Royal College of Surgeons of England Prospective audit development

Introduction Prospective audit designed to address two key concerns: The management of men with low-risk disease – Are patients being over-treated that could be appropriately managed by active surveillance? Use of multimodality therapy * for men with high-risk localised or locally advanced prostate cancer – Are these patients being under-treated? *hormones and external beam radiotherapy; surgery followed by adjuvant or early salvage radiotherapy

Prospective audit Data collection started on the 1 st April 2014 in England: – Characteristics of all newly diagnosed men, how their cancer was detected & the referral pathway – Crucial steps in the diagnostic & staging process – The planning of initial treatment & initial treatments given NPCA will also systematically measure the functional impact of radical therapies on patients’ lives (PROMs/PREMs) – 18 months’ after diagnosis Provide key information on current practice and outcomes: – Early complications, longer term survival & quality of life – Compared with NICE Quality Standards – Generate QPIs

Design of the NPCA MDS: key principles All men with newly diagnosed prostate cancer Data on their diagnosis, staging and initial treatment should be collected during the initial phase of management and available at meetings of the MDT – ‘All patients with a new diagnosis of PC should be discussed at a MDT meeting’ NICE 2002 The burden of data collection on staff and patients should be kept to a minimum The audit data items should be available soon after they are generated in clinical practice

A new generation of national cancer audit Key characteristics of NPCA prospective audit: – based on Cancer Outcomes and Services dataset (COSD) items as much as possible – National Cancer Registration Service (NCRS) is data collection partner Developed ‘minimum dataset (MDS)’ – Project team in consultation with stakeholders – Utilised COSD items, BAUS & created NEW items where appropriate – 50 data items in total (now 49 – 2xCOSD items removed) – only 20 new data items (now 21)

NPCA contact database developed & updated – Communication with trust teams about the audit NPCA Prospective Audit Information Package – Detailed data set specification – Data dictionary & guidance document – Summary handout & FAQ MDT system suppliers – 50% of trusts use Somerset, 25% InfoFlex, 25% ‘Other’ – Worked with Somerset and Infoflex to implement within systems NCRS regional offices – Coordination of CG approval & distribution of NPCA Information Package (also – Help-desk function for trusts – Accept test extracts as local IT teams upgrade MDT systems MDS implementation: England

Mechanism for collection & submission of data for the NPCA mirrors COSD Frequency of data submission is monthly by designated dates post diagnosis/treatment, e.g: November 2014 data by 6 th January 2015 December 2014 data by 5 th February 2015 NPCA data is subsequently exported from MDT software systems and submitted to local NCRS offices along with routine COSD submission It was anticipated that it may take a few months to fully implement appropriate mechanisms for data collection & to align with COSD submission schedule Possible to plug data gaps at a later submission Participation has increased month on month Update from Regina, NCRS including launch of monthly Quality Reports (data completeness) Collection & submission of data: England

Schematic of NPCA data collation

Included in NHS Wales National Clinical Audit and Outcome Review plan – Participation is mandated Mechanism for data collection & submission is currently being developed NHS Wales Information Service are developing software updates to the national Canisc system – Mapping NPCA dataset NPCA has received confirmation that the data collection process in Wales will start in April 2015 – NPCA will work with colleagues in Wales during implementation of the MDS & dissemination of the necessary guidance Collection & submission of data: Wales

NPCA Prospective Audit MDS MDS 1. all newly diagnosed men with PC during MDT meeting (s) to discuss initial phase of treatment – more detail and data item change in the following slides MDS 2. all men with PC who have undergone radical prostatectomy – Paul will explore in more detail and explain data item changes MDS 3. all men with PC for whom external beam radiotherapy or brachytherapy +/- androgen deprivation therapy are planned – Ajay will explain rationale behind collection of planned items and propose mechanism for data collection

MDS 1: introduction 9 routinely collected mandated COSD items: patient identity & demographic details; NHS Trust/MDT/Consultant Collect clinical data on the patient, their cancer and their initial treatment plan (summary handout in delegate pack) – 20 clinical items in total : 11 in COSD, 9 new items including 2 in RCPath

MDS 1: Case-mix adjustment NPCA will take account of differences in mix of patients between providers – Age & ethnicity, socioeconomic status, overall physical condition, comorbidity and pre-existing urinary symptoms

MDS 1: Source of referral Approx. 25% patients first diagnosed with cancer after an emergency hospital admission – Early detection is an important determinant of treatment outcome NPCA will determine variation in the way PC is diagnosed – Geographical variation, relationship with disease stage at presentation, treatment allocation and ultimately outcomes

MDS 1: Risk Stratification NPCA will collect information on a patient’s definitive diagnosis of PC – Biopsy type, biopsy histology, D’Amico risk stratification

MDS 1:Multiparametric MRI NPCA will determine whether men undergo mpMRI before prostate biopsy as an initial step in the diagnostic pathway

MDS 1: Patient pathways NPCA will determine the patient pathway following diagnosis – type/s of clinical specialist men are seen by and in what setting

MDS 1 data item change: Planned treatments ‘Planned prostate cancer treatment’ was captured during MDT prior to discussion with patient – ‘back mapped’ to COSD item ‘Planned treatments’ – ‘all options’ captured = limited utility NPCA will collect: Planned Prostate Cancer Treatment agreed with the Patient – Treatment plan agreed with the patient – only one plan (may be a combination of radiotherapy and hormones)

Thank You